Two studies recently reported around 10% of EGFR activating mutations in triple negative breast cancers from Asian patients. However, we did not find any EGFR activating mutation in a series of 229 breast tumor samples from European patients. Like in lung cancer, the EGFR mutation profiles seem to be related to the ethnical origin of patients. This is an important point that should be considered when developing anti-EGFR therapies.
and 21 EGFR mutations [7] . These results underline geographic differences in the presence of EGFR activating mutations as it was already described for non-small cell lung cancer [8] . This mutational event, which appears to be mostly limited to Chinese patients with TN breast cancer, could be related to ethnic or environmental factors. However, the question of the origin of the geographical variations in the occurrence of EGFR mutations in lung and breast cancers is unresolved.
Interestingly, a case of breast metastasis from a primary lung cancer that was confirmed by the detection of the same EGFR mutation has been recently reported [9] . This observation confirms that the presence of this mutation is not an obstacle to metastasization/tumor cell growth in the breast microenvironment. Inversely, we should not forget that some breast cancer characteristics, like ER expression and HER2 over-expression, have been also described in lung cancers [10, 11] . Lung and breast cancer subtypes seem to share some biomarkers and thus could respond to the same therapies.
At the time of personalized medicine in oncology, more than ever, molecular patterns break the limits of classifying tumors according to their localization. Mutation profiles have to be analyzed in sub-groups of specific populations. This is a new and promising challenge for the design of clinical trials involving targeted therapies. 
